Gilead Sciences and Goldfinch Bio signed a multiyear deal that aims to research, develop and market new therapies for orphan and diabetic kidney diseases, with targets coming from Goldfinch's proprietary Kidney Genome Atlas. The agreement could generate more than $2 billion for Goldfinch.
Gilead, Goldfinch collaborate on kidney disease R&D
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.